#Lipoproteina

A sweeping new international study has reinforced the dangers of elevated lipoprotein(a) – called Lp(a) – showing that any detectable increase in this cholesterol-like molecule is linked to greater risk of heart disease and stroke. The findings, widely reported as the largest investigation of its kind to date, signal a major shift in how health professionals may assess and manage cardiovascular risk, especially in populations such as Thailand where heart disease remains the country’s leading cause of death.

A large international study confirms that even small increases in lipoprotein(a), or Lp(a), are linked to higher risks of heart disease and stroke. The research, one of the biggest investigations of its kind, suggests clinicians should rethink how cardiovascular risk is assessed, particularly in Thailand where heart disease remains the leading cause of death.

Lp(a) is a blood particle similar to LDL cholesterol but with an extra protein that makes it sticky and more likely to promote clots and plaque. Unlike traditional cholesterol, Lp(a) levels are largely genetic and resistant to lifestyle changes or common cholesterol-lowering medicines. The study’s scale—encompassing hundreds of thousands of participants—highlights that even modest Lp(a) elevations deserve clinical attention. Research from Medical Xpress synthesizes these international findings for a broad audience.